Why Is PGEN Stock Rising Today? Precigen Surges After Q2 Return to Profitability

Precigen (PGEN) shares rose 11.03% in pre-market trading Wednesday after the company reported second-quarter 2026 results that marked a return to profitability.

What Did Precigen Report?

For the quarter ended June 30, Precigen posted net income of $20.1 million, a sharp reversal from the $26.6 million net loss in the same period a year earlier. Revenue surged to $55.0 million, driven by sales of PAPZIMEOS, the company's gene therapy product.

The results, released after the market close on August 4, represent a dramatic swing from the prior year, when the company was still operating at a loss.

Why Did Investors React?

The move from loss to profit signals a fundamental financial turnaround. The $55.0 million revenue figure, powered by PAPZIMEOS, suggests the lead product is gaining meaningful commercial traction.

For a company that was loss-making a year ago, reaching profitability indicates the product may be reaching a scale that can sustain the business. The 11.03% pre-market gain reflects investor optimism about the pace of the turnaround, though pre-market liquidity is thinner than during regular trading and the move may not fully capture institutional sentiment.

What Comes Next?

The regular trading session will provide a clearer read on how institutional investors are processing the results.

The sustainability of PAPZIMEOS revenue is the central question. One quarter of strong sales does not guarantee a durable trend, and investors will watch for signs of continued commercial momentum in the quarters ahead. Any additional details from the company about the product's commercial trajectory or pipeline milestones could also shape the stock's direction.